Breckenridge Pharmaceutical, Inc. and Chemo/Liconsa (Spain) Agree to Develop and Market Generic ANDA

Jun 29, 2007, 01:00 ET from Breckenridge Pharmaceutical, Inc.

    BOCA RATON, Fla., June 29 /PRNewswire/ -- Breckenridge announced that
 it has entered an agreement with Chemo/Liconsa (Madrid, Spain) to develop
 and manufacturer terbinafine, generic version of Lamisil(R) tablets. The
 market for Lamisil(R) exceeds $800 million. Breckenridge signed a Letter of
 Intent in February 2007 to secure the marketing in the US for the ANDA;
 which is filed and pending FDA approval. FDA recently acknowledged the
 transfer of the ANDA to Breckenridge, and final approval is expected soon.
     Breckenridge has an aggressive Product Development program and looks
 forward to adding more products to its ANDA portfolio.
     About Breckenridge:
     Breckenridge Pharmaceutical is a privately held pharmaceutical
 marketing, research and development company founded in 1983 that markets a
 broad range of ValuBrand(TM) and Generic prescription products in many
 therapeutic categories. The Breckenridge label is widely accepted in over
 100 accounts; including Wholesalers, Distributors, Chains, and Managed Care
 Accounts, as well as Retail Pharmacies nationwide. The company markets 100
 products, more than 150 sku's, in most dosage forms including: Tablets,
 Capsules, Soft Gel Capsules, Liquids, Suspensions and Topical preparations.
     About Chemo/Liconsa:
     Chemo/Liconsa is a chemical-pharmaceutical company, dedicated to the
 development, manufacture and commercialization of Active Pharmaceutical
 Ingredients and Finished Dosage Forms for the pharmaceutical industry, with
 a focus on the generic industry; as well as the commercialization of
 pharmaceutical specialities in the gynecological area. Chemo relies on 10
 industrial facilities in Europe, Asia and Latin-America.
     Lamisil(R) is a registered trademark of Novartis

SOURCE Breckenridge Pharmaceutical, Inc.